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Compartment-resolved Proteomic Analysis of
Mouse Aorta during Atherosclerotic Plaque
Formation Reveals Osteoclast-specific Protein
Expression*□S
Michael Wierer‡a, Matthias Prestel§a, Herbert B. Schiller‡¶, Guangyao Yan§,
Christoph Schaab‡, Sepiede Azghandi§, Julia Werner, Thorsten Kessler,
Rainer Malik§, Marta Murgia‡**, Zouhair Aherrahrou‡‡§§, Heribert Schunkert¶¶,
Martin Dichgans§, and Matthias Mann‡
Atherosclerosis leads to vascular lesions that involve ma-
jor rearrangements of the vascular proteome, especially
of the extracellular matrix (ECM). Using single aortas from
ApoE knock out mice, we quantified formation of plaques
by single-run, high-resolution mass spectrometry (MS)-
based proteomics. To probe localization on a proteome-
wide scale we employed quantitative detergent solubility
profiling. This compartment- and time-resolved resource
of atherogenesis comprised 5117 proteins, 182 of which
changed their expression status in response to vessel
maturation and atherosclerotic plaque development. In
the insoluble ECM proteome, 65 proteins significantly
changed, including relevant collagens, matrix metallo-
proteinases and macrophage derived proteins. Among
novel factors in atherosclerosis, we identified matrilin-2,
the collagen IV crosslinking enzyme peroxidasin as well
as the poorly characterized MAM-domain containing 2
(Mamdc2) protein as being up-regulated in the ECM
during atherogenesis. Intriguingly, three subunits of
the osteoclast specific V-ATPase complex were strongly
increased in mature plaques with an enrichment in
macrophages thus implying an active de-mineralization
function. Molecular & Cellular Proteomics 17: 10.1074/
mcp.RA117.000315, 321–334, 2018.
Vascular diseases result in almost 18 million fatalities world-
wide per year, making them the leading cause of death (1).
The underlying pathophysiology is often atherosclerosis and
the most common clinical manifestations are stroke and cor-
onary artery disease (CAD)1 (2–5). Atherosclerosis is a chronic
inflammatory condition characterized by an accumulation of
lipids in the arterial wall, together with infiltration of mono-
cytes and other immune cells, leading to the development of
an atheromatous plaque. Over time, apoptotic and necrotic
cells together with cholesterol crystals form a necrotic core.
The surface of advanced plaques is covered by a fibrous cap
of variable thickness, composed of a dense collagen-rich
extracellular matrix (ECM) and sparsely distributed cells, in
particular, vascular smooth muscle cells (VSMCs). In late
stages, the expression of proteases can destabilize the cap,
inducing plaque rupture and thrombosis, which may manifest
as stroke or myocardial infarction (6–11). Thus, plaque stabil-
ity is directly related to clinical events (12).
The arterial wall structure of vertebrates is subdivided into
the tunica intima, media and adventitia, comprising endothe-
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lial cells, VSMCs and a heterogeneous population of myofi-
broblast cells. These cells are embedded in an ECM to pro-
vide the biomechanical properties required for vessel function
(13–15). The endothelial cells of the tunica intima demark the
border to the blood and are crucial in the initial phase of
atherogenesis. Systemic risk factors such as hypercholester-
olemia, high blood pressure, and disturbed laminar flow in-
duce endothelial dysfunction, subendothelial lipid deposition
and leukocyte extravasation (16). Continuous invasion of leu-
kocytes and VSMCs, and the differentiation of macrophages
to foam cells elicit cytokine and chemokine secretion, leading
to inflammation and to the development of an atherosclerotic
plaque. The arterial ECM is critically involved in signaling
processes relevant to atherosclerosis and undergoes sub-
stantial changes during atherogenesis (17–23). Several stud-
ies link ECM components to vascular inflammation and ath-
erosclerotic plaque development (reviewed in (22)), yet our
understanding of the underlying protein expression changes
is mainly limited to the study of individual factors or small sets
of proteins.
Recent application of “omics” methodologies (24), espe-
cially of high resolution mass spectrometry (MS), has allowed
the categorization of the ECM constituents in “core matri-
some” and “matrisome-associated” proteins (25–27). The
core matrisome is a multifunctional matrix composed of col-
lagens, proteoglycans and glycoproteins. It provides a biome-
chanical scaffold, with space-filling and lubrication functions,
and plays a role in signal transduction, cell adhesion and
many additional physiological processes (28, 29). The matri-
some-associated proteins include secreted factors (such as
cytokines and chemokines some of which are tightly bound to
the ECM), ECM regulators (such as proteinases) and ECM-
affiliated proteins (such as galectins) (25).
Although the proteome and secretome in atherosclerosis
has been studied by proteomics in mouse models and human
samples (30–32), an overall and in-depth picture of the pro-
gressive changes during atherogenesis of the protein compo-
nent of the plaque in general and the ECM is currently lacking
(33). MS based analysis of the ECM is challenging because of
the insolubility of ECM components as well as contamination
from more abundant intracellular proteins (33). Stepwise ex-
traction protocols, in which a biological sample is fractionated
according to the solubility of the contained proteins have
been described, partially overcoming these limitations (26,
34–37).
To increase our understanding of protein changes in
atherogenesis, we sought to study proteome changes with
special focus on ECM proteins in an unbiased way. Using
advances in MS-based proteomics (38), our laboratory has
recently developed a very sensitive and in-depth approach
termed quantitative detergent solubility profiling (QDSP) and
applied it to unravel matrisome changes during lung injury in
great depth (39). Here we applied the QDSP protocol to ApoE
knock out mice (ApoE/), a classical mouse model for ath-
erosclerosis. These mice develop intermediate and advanced
plaques at 16 and 24 weeks, respectively, when fed a high-fat,
“western-type” diet (40, 41). We generated a quantitative and
in-depth resource of time- and compartment-resolved pro-
teome changes of the aorta during atherogenesis. Analysis
and replication in an independent cohort retrieved key known
factors and uncovered novel proteins pointing to hitherto
unknown activities in atherosclerotic plaques.
EXPERIMENTAL PROCEDURES
Experimental Design and Statistical Rationale—In total, 38 aortas
from individual mice were analyzed to generate the data set. For each
biological condition (defined by time point, genotype and cohort) we
used 3–5 aortas and analyzed them as biological replicates in single
injection MS measurements. The control group were age and sex-
matched wild type mice (8 weeks, n  5; 16 weeks; n  5; 24 weeks:
n  3). Statistical comparisons were performed within cohorts over
different biological conditions via ANOVA applying randomization-
based FDR control for unequal variance.
Animal Experiments—All animal protocols were approved by the
government of Upper Bavaria (AZ:175–13) and Schleswig-Holstein
(AZ:122–4 (108–9/11)). Mice had ad libitum access to food and water
and were housed under a 12h light dark cycle. All experiments were
done on male littermates (C57BL76J or ApoEtm1Unc) fed with standard
chow diet. In case of the ApoEtm1Unc mice a high-fat diet (TD88137,
Harlan) was administered at 8 weeks age for either 8 or 16 weeks.
Animals were sacrificed at age 8, 16 or 24 weeks by an overdose of
ketamine and xylazine. The arterial tree was perfused through the left
ventricle with 20 ml 0.9% sodium chloride solution. For quantitative
detergent solubility profiling (QDSP) aorta were dissected from the
ascending part until the bifurcation to the renal arteries and snap
frozen in liquid nitrogen and subsequently stored at 80 °C. For
histology, the aortic arch and its main branches were dissected and
fixed for 24h in 1% PFA solution. The aortic arch was embedded in
paraffin and cut into consecutive 4 m sections using a microtome.
Immunohistochemistry—Antibodies against Mamdc2 (HPA021814,
Sigma-Aldrich, Taufkirchen, Germany), and Tcirg1 (sc-162300, Santa
Cruz Biotechnology, Dallas, TX) were titrated to optimize their working
dilution. For subsequent signal amplification the Tyramide signal am-
plification kit with Cyanine 3 (Cy3) (NEL704A001KT, PerkinElmer,
Waltham, MA) was used according to the manufacturer’s instruction.
To achieve co-staining of macrophages in aortic plaques MAC2
(CL8942AP, Cedarlane, Burlington, Canada) was used together with
Alexa 647 conjugated F(ab)2 Fragment (112–606-003, Jackson lab-
oratory, Bar Harbor, ME). Confocal imaging was performed on laser
scanning confocal with airyscan (Zeiss LSM 880).
Sample Preparation Procedures for Proteome Analysis - QDSP—
QDSP of mouse aorta was performed following a previously pub-
lished protocol with minor modifications (39). Aorta were disrupted in
PBS containing 1x protease inhibitor mixture with EDTA (PIC, Roche,
Penzberg, Germany) using a micro tissue grinder (Thermo-Fisher
Scientific, Waltham, MA). After centrifugation (20 min at 16,000  g)
the supernatant was collected and the pellet resuspended in buffer 1
(150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 5% Glycerol, 1% IGEPAL-
CA-630 (Sigma-Aldrich), 1 mM MgCl2, 1x PIC, 1% Benzonase
(Merck, Burlington, MA), 1x PIC). After 20 min incubation on ice, the
extract was centrifuged and the supernatant collected and combined
with the first supernatant (FR1). The pellet was resuspended in buffer
2 (50 mM Tris-HCl pH 7.5, 5% glycerol, 150 mM NaCl, 1.0% IGEPAL
CA-630, 0.5% sodium deoxycholate, 0.1% Sodium Dodecyl Sulfate
(SDS), 1% Benzonase (Merck), 1 PIC), incubated on ice for 20min
and centrifuged. The supernatant was collected (FR2), the pellet
resupended in buffer 3 (50 mM Tris-HCl pH 7.5, 5% glycerol, 500 mM
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NaCl, 1% IGEPAL CA-630, 2% sodium deoxycholate, 1% SDS, 1%
Benzonase and 1 PIC), and incubated at room temperature for 20
min. Following centrifugation, the supernatant was collected (FR3)
and the insoluble pellet resuspended in PBS  PIC (INSOL).
All four fractions were acetone precipitated and subjected to in-
solution digest as previously described (39, 42). Precipitates were
resuspended in denaturation/reduction/alkylation buffer (6 M guani-
dinium hydrochloride (Sigma-Aldrich), 100 mM Tris-HCl pH 8, 10 mM
TCEP (Thermo-Fisher Scientific), 50 mM CAA (Thermo-Fisher Scien-
tific)), incubated at 99 °C for 10 min and sonicated 15 min in a
Bioruptor (Diagenode, Liége, Belgium) at high setting with 30 s on
30 s off cycles. Samples from FR1–3 were diluted 10-fold with dilution
buffer (10% acetonitrile) and digested over night with Trypsin (Sigma-
Aldrich) and LysC (Wako, Neuss, Germany) (1:20 enzyme to protein
ratio for each enzyme) at 37 °C. Samples of the INSOL fraction were
diluted with 1:1:1 with dilution buffer and U/T buffer (6 M urea, 2 M
thiourea) followed by addition of 2.5 g Lys-C and mechanical dis-
ruption applying 200 strokes in a micro tissue grinder. The resulting
mixture was sonicated again 15min in the Bioruptor and incubated 3 h
at 37 °C under vigorous shaking conditions. The predigested samples
were diluted 1:3.3 with dilution buffer and digested over night by
addition of 2.5 g Trypsin and 2.5 g Lys-C at 37 °C.
Peptides of all four fractions were desalted using stage-tips con-
taining a Poly-styrene-divinylbenzene copolymer modified with sul-
fonic acid groups (SDB-RPS) material (3M, St. Paul, MN) as previously
described (42).
LC-MS/MS Analysis—Peptides were separated on a reverse phase
column (50 cm length, 75 m inner diameter) packed in-house with
ReproSil-Pur C18-AQ 1.9 m resin (Dr. Maisch GmbH, Ammerbuch,
Germany). Reverse-phase chromatography was performed with an
EASY-nLC 1000 ultrahigh pressure system, coupled to a Q-Exactive
HF Mass Spectrometer (Thermo Scientific). Peptides were loaded
with buffer A (0.1% (v/v) formic acid) and eluted with a nonlinear
120-min gradient of 5–60% buffer B (0.1% (v/v) formic acid, 80% (v/v)
acetonitrile) at a flow rate of 250 nl/min. After each gradient, the
column was washed with 95% buffer B and re-equilibrated with buffer
A. Column temperature was kept at 50 °C by an in-house designed
oven with a Peltier element and operational parameters were moni-
tored in real time by the SprayQc software. MS data were acquired
with a top15 shotgun proteomics method, where in each cycle a full
scan is followed by up to 15 data-dependent MS/MS scans. Target
value for the full scan MS spectra was 3  106 charges in the
300–1650 m/z range with a maximum injection time of 20 ms and a
resolution of 60,000. Isolation of precursors was performed with the
quadrupole at window of 1.4 m/z. Precursors were fragmented by
higher-energy collisional dissociation (HCD) with normalized collision
energy (NCE)/stepped NCE of 27. MS/MS scans were acquired at a
resolution of 15,000 with an ion target value of 1  105, a maximum
injection time of 25 ms, and an underfill ratio of 10%. Repeated
sequencing of peptides was minimized by a dynamic exclusion time
of 20 s.
Computational MS-data Analysis—MS raw files were analyzed by
the MaxQuant software (43) (version 1.5.3.29) and peak lists were
searched against the mouse Uniprot FASTA database (UP000000589_
10090.fasta and UP000000589_10090_additional.fasta, version June
2015), and a common contaminants database (247 entries) by the
Andromeda search engine. Cysteine carbamidomethylation was set
as fixed modification, methionine oxidation and N-terminal protein
acetylation as variable modifications. False discovery rate was 1% for
proteins and peptides (minimum length of 7 amino acids) and was
determined by searching a reverse database. Peptide specificity was
set to trypsin requiring C-terminal arginine or lysine with a maximum
of two missed cleavages. Maximal allowed precursor mass deviation
for peptide identification was 4.5 ppm after time-dependent mass
calibration and maximal fragment mass deviation was 20 ppm.
“Match between runs” was activated with a retention time alignment
window of 20 min, and a match time window of 0.7 min to increase
protein identification. For total proteome analyses, solubility fractions
were defined in MaxQuant for a combined protein MaxLFQ output,
with a minimum ratio setting of 2. For fraction specific analyses no
fraction information was predefined and the minimum ratio setting
was 1. Protein abundance estimates were calculated by dividing
MaxLFQ values by the theoretical number of tryptic peptides per
protein.
Statistics—All downstream bioinformatic analyses were performed
with Perseus (44) (versions 1.5.3.0 and 1.5.5.5) and R (version 3.2.2).
Protein groups only identified by site FDR, only from peptides iden-
tified also in the reverse database, or belonging to IgG subtypes were
excluded from the analyses. For fraction specific analyses, MaxLFQ
protein intensity values were filtered for at least two different pep-
tides. For PCA, ANOVA and Student’s t test, missing values were
imputed with a width of 0.2 and a downshift of 1.8 over the total
matrix. ANOVA was performed in Perseus with s0 set to 0 and
subsequent filtering for a minimum fold change of 1.5-fold. Gene
annotation enrichment analyses were done with Fisher’s exact test
including GOMF, GOCC, GOBP, and Corum annotations, curated
gene lists of matrisome (25, 26), immune cell signatures (45, 46), and
gene lists taken from Ingenuity Pathway Analysis (IPA, Qiagen, Hilden,
Germany). Minimum FDR was set to 0.1 and annotation lists filtered
for the presence for at least three proteins in the intersection. St-
udent’s t test was performed with the SAM package in R (47). The
logarithmized MaxLFQ intensities were filtered to have at least two
valid values in one of the replicates of a single time point. Missing
values were imputed as described before and t test statistics calcu-
lated using the samr function (s0  0.2, nperm  1000). Delta tables
were computed using the samr function with a minimal fold change of
2 and significant outliers defined by the smallest delta value allowing
identification of the highest number of significant outliers with a
median FDR  0.1.
RESULTS
Quantitative Detergent Solubility Profiling (QDSP) of Mouse
Aorta—To follow atherosclerotic plaque development by pro-
teomics, we fed 8 week old atherosclerosis prone ApoE/
mice for 8 and 16 weeks with a high-fat, western-type diet
(Material and Methods) (Fig. 1A) resulting in consistent forma-
tion of atherosclerotic lesions (supplemental Fig. S1A). As
controls, we used age- and sex-matched wild-type mice fed
with chow diet, avoiding spontaneous plaque formation. For
an independent evaluation of our data, we included a second
ApoE/ mouse cohort, which was kept in a different mouse
facility. Per cohort, each biological condition consisted of
three to five individual animals.
To gain insight into the cellular localization of proteins we
applied the QDPS protocol (39). Briefly, we lysed individual
aortas in buffer with low detergent strength, pelleted homog-
enized material by centrifugation and performed consecutive
extraction steps with buffers containing increasing detergent
concentrations. The resulting insoluble fraction was mechan-
ically sheared and all fractions enzymatically digested by tryp-
sin and LysC. Although the first QDPS fractions contained
about 50–100 g, peptide amounts in the more insoluble
ones were about hundred-fold lower. For each aorta we quan-
tified 3756–4728 proteins (median 4,265) using label-free val-
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FIG. 1. Quantitative detergent solubility profiling of mouse aorta. A, Outline of the experimental setup. Two independent ApoE/mouse
cohorts and one paired wild-type mouse cohort were analyzed at the age of 8, 16 and 24 weeks (n  3 - 5 mice per time point). Aortas were
prepared and proteins sequentially extracted with buffers of increasing detergent strength. Proteins from the four different fractions were
digested with trypsin and analyzed by high-resolution mass spectrometry in a label free shotgun approach. B, Principal component analysis(PCA)
reveals a clear separation of the four fractions in the first two components.C, Protein loadings of the PCA shown in (B).D, QDSP profiles for selected
proteins of cohort #1. Data points are filtered for the presence of at least two valid values and are averages. Error bars represent S.E.
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ues (MaxLFQ) calculated by the MaxQuant software (43, 48)
(supplemental Table S1, supplemental Fig. S1B). We achieved
high technical and biological reproducibility as reflected in
Pearson correlation coefficients above 0.90 for all aorta pro-
teomes (supplemental Fig. S1C).
Reproducibility was also high at the level of individual frac-
tions as evident from principal component analysis (PCA) (Fig.
1B). The four fractions clearly separated in the PCA plot in
the first two components, despite being collected from two
different and independently processed cohorts. cytosolic pro-
teins such as the proteasome complex core members
showed specific enrichment toward the first fraction (FR1),
membrane proteins such as the NADH dehydrogenase com-
plex were localized between FR1 and FR2 (Fig. 1C). The
tropomyosin associated troponin complex specifically puri-
fied in FR2, and nucleosomal proteins distributed over FR2
and FR3. As expected, the ECM proteins such as collagens
were preferentially enriched toward the insoluble fraction
(FR4). The robustness of the protocol at the level of individual
protein is exemplified by the highly reproducible profiles of
Transforming Growth Factor Beta Induced (Tgfbi), Protea-
some Subunit Beta 5 (Psmb5), and Histone H3.3 (H3f3a)
across different time points, conditions and cohorts analyzed
(Fig. 1D, supplemental Fig. S1D). This in-depth proteomic
data set of mouse aorta during atherogenesis robustly reports
on the compartmentalization of proteins within the tissue
based on their detergent solubility profiles.
Atherogenesis and Vessel Maturation Lead to Distinct Pro-
teome Changes in the Aorta—The changes in the aortas of our
mouse cohorts are because of normal maturation and athero-
genesis induced changes in these vessels as well as to plaque
formation in the ApoE/ mice. Note that these plaques con-
stitute only a few percent of aorta mass, requiring accurate
and in-depth differential quantification of the proteomes.
From our data set, we first calculated protein changes of all
four QDPS fractions together, taking advantage of the accu-
rate MaxLFQ normalization implemented in the MaxQuant
software (48). Vessel maturation likely occurs to the same
extend in both genotypes, whereas atherogenesis-specific
changes should only manifest in the ApoE/ and high-fat fed
mice. To define significantly regulated proteins, we therefore
performed one-way ANOVA analysis between the genotypes
in all of the three time points. Requiring a minimum fold
change of 1.5-fold over the average expression level in the
biological replicates resulted in 182 significantly regulated
proteins in cohort 1 at a False Discovery Rate (FDR) below
0.05 (supplemental Table S2; Fig. 2A). Comparing the expres-
sion changes of this set of proteins in the independent cohort
2, revealed very high reproducibility of fold changes (r 0.91),
clearly validating our findings (Fig. 2B).
Unsupervised hierarchical clustering of significantly regu-
lated proteins revealed four major groups (Fig. 2A). Although
Cluster 2 and 3 contain proteins regulated in response to
vessel maturation independently of the genotype, the ones in
Cluster 1 and 4 were specifically regulated during atherogen-
esis in ApoE/ mice. Cluster 4 contained a large number of
known factors related to atherosclerotic plaque development
that were up-regulated at the 16 week and particularly the 24
week time points in the knock-out mice. This included the
endothelial expressed vascular cell adhesion molecule-1
(Vcam-1) responsible for recruitment of immune cells (49), the
macrophage derived Cathepsins B and D (Ctsb/Ctsd) (50),
Galectin-3 (Mac2) (51), as well as apoptosis inhibitor of
macrophage (AIM/Cd5l) (52), serving as positive controls for
atherogenesis mediated recruitment and invasion of mono-
cytes. The proteins with highest regulation in response to the
genotype were also robustly enriched in individual t test com-
parisons of ApoE/ and wild type aortas at the three different
time points (supplemental Fig. S2A–S2C).
Bioinformatic “annotation enrichment analysis” in Cluster 4
revealed a high prevalence of proteins of the matrisome com-
partment (25, 26), immune cell gene signatures (45, 46) (p 
0.01), as well as of the gene lists “atherosclerosis” and “vas-
cular lesion” from Ingenuity pathway analysis (IPA) (p 
1011; Fig. 2C, supplemental Table S3). Further supporting
our analysis, Cluster 4 was specifically enriched for Gene
Ontology (GO) annotations related to known molecular pro-
cesses in atherogenesis, including “chemotaxis” (p  104),
“integrin binding” (p  107) and “secreted” protein (p 
1032). Interestingly, proteins related to “morphology of bone”
(p  107) and “mineralization of bone” (p  103) were also
enriched, pointing to vascular calcification a crucial event in
atherogenesis. Our proteomic data directly provides the iden-
tity of the proteins responsible for these annotation enrich-
ments (supplemental Table S4).
In addition to a large set of proteins that are biologically
linked to atherogenesis, we discovered several factors with-
out previous connection to atherosclerosis. One of these is
Coactosin-like protein (Cotl1), a chaperone for the Arachido-
nate 5-lipoxygenase (Alox5) (Fig. 2D). Alox5 catalyzes an initial
step in the biosynthesis of leukotrienes, mediators of smooth
muscle cell contraction that act as strong activators of inflam-
mation when overexpressed. Polymorphisms in genes in-
volved in the leukotriene pathway have been linked to ather-
osclerosis in humans and Alox5 itself is a key molecule for
atherosclerosis susceptibility in mice (7, 53). As Alox5 stabi-
lization by Cotl1 leads to increased activity because of an
inactivation of protein turnover (54), the up-regulation of Cotl1
observed here may contribute to the activation of the leuko-
triene pathway during atherogenesis. Another up-regulated
protein not previously linked to atherogenesis is Annexin A8
(Anxa8) (Fig. 2D). Loss of Anxa8 results in a reduction of the
leukocyte adhesion factor P-selectin and its cofactor CD36 at
the cell surface (55). Conversely, the up-regulation of Anxa8
during atherogenesis observed here may increase leukocyte
recruitment to aortic endothelial cells.
We also identified proteins that were specifically downregu-
lated in atherogenic ApoE/mice compared with nonathero-
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FIG. 2. Total proteome changes during atherogenesis. A, Unsupervised hierarchical clustering of significantly (ANOVA, FDR  0.05, fold
change 1.5 1.5) regulated proteins (z-scored MaxLFQ values) analyzing all fractions of the first cohort together. B, Correlation of protein
fold changes (ApoE/, 24 weeks versus 8 weeks) of both cohorts reveals low variation. C, Gene annotation enrichment analysis of proteins
from each cluster versus all quantified proteins. In addition to Gene Ontology (GO) annotations (no shading), annotations included extracted
gene lists from Ingenuity pathway analysis (IPA) (yellow shading), immune cell gene signatures (Gautier et al., 2012; Jojic et al., 2013) (purple
shading), as well as curated lists of matrisomal proteins (Naba et al., 2012a; Naba et al., 2012b) (blue shading) obtained from the literature. D, Cotl1
QDPS profile of cohort #1. Data points are filtered for the presence of at least two valid values and are averages. Error bars represent S.E.
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genic wild type mice at the age of 16 and 24 weeks (Fig. 2A).
Podocan (Pdn), is an inhibitor for the migration and prolifera-
tion of VMSCs in mice and humans (56). As Pdn/ mice
show increased neointima formation after arterial injury, its
down-regulation might be functionally associated with plaque
development. Similarly, the GTPase Rrad (Ras associated
with diabetes) suppresses the attachment and migration of
VSMCs (57).
Atherosclerosis in General and the ApoE/ Phenotype in
Particular are Closely Linked to Lipid Metabolism and Trans-
port—In our data set, 25 out of the 90 proteins that were
differentially regulated between wild-type and the ApoE/
mice on the high fat diet were related to lipid metabolism and
transport (supplemental Fig. S2D). Most of those proteins
were up-regulated specifically during atherogenesis - such as
Apolipoprotein B (Apob) and Apolipoprotein A-IV (Apoa4). In
contrast, Apolipoprotein A-I (Apoa1) was about 2-fold down-
regulated and we attribute this to the ApoE knock out rather
than to atherogenesis because it was the case at all time
points.
Interestingly, palmitoyl protein thioesterase 1 (Ppt1) was
specifically up-regulated in ApoE/ mice after 16 weeks,
corresponding to 8 weeks of high-fat diet (supplemental Fig.
S2D). Ppt1 is a lysosomal hydrolase that removes long fatty
acid sidechains such as palmitate from proteins. Mutations in
the Ppt1 genes cause infantile neuronal ceroid lipofuscinosis
(58), a severe neurodegenerative disease characterized by an
accumulation of ceroid aggregates in lysosomes and leading
to neuronal death. As ceroid formation has been also ob-
served in atherosclerotic plaques (59), the up-regulation of
Ppt1 during atherogenesis may represent a regulatory mech-
anism aimed at the removal of ceroids.
The Osteoclastic V-ATPase Complex is Expressed in Macro-
phages of Mature Atherosclerotic Plaques—Vascular calcifi-
cation is a hallmark of atherogenesis, leading to arterial stiff-
ening and mineralization of atherosclerotic plaques (60).
Several proteins known to promote calcification were specif-
ically expressed in the ApoE/ mice during the latest time
points of atherogenesis, including Osteoactivin (Gpnmb), Os-
teopontin (Spp1), Bone sialoprotein 2 (Ibsp), matrix Gla pro-
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tein (Mgp) and proteoglycan 4 (Prg4) (Fig. 3A). Interestingly,
two inhibitors of calcification, Osteoprotegerin (Tnfrsf11b) (61)
and Cartilage oligomeric matrix protein (Comp) (62) were also
increased, suggesting an interplay of positive and negative
regulators of vascular calcification.
The mechanisms of vascular calcification resembles the
calcification processes in bone (63). Bones are continuously
remodeled by decalcifying osteoclast cells derived from the
monocyte-macrophage lineage, which balance calcification
by the osteoblasts. Aside from secreting enzymes that de-
grade organic matter, osteoclasts release H and Cl- ions to
dissolve inorganic matrix by means of a vacular-type H-
ATPase in the plasma membrane, containing three subunits
specific to osteoclasts (Tcirg1, Atp6v0d2, and Atp6v1b2). Un-
expectedly, we identified all three subunits to be specifically
present and up-regulated in atherosclerotic aortas (Fig. 3B).
Although we detected Tcirg1 and Atp6v0d2 exclusively in
24-week-old ApoE/ mice, Atp6v1b2 was expressed in all
conditions, with a specific increase in 24-week-old ApoE/
mice. We next asked which cell type expressed this complex.
Immunohistochemistry (IHC) against Tcirg1 showed a clear
Tcirg1 staining of Mac2-marked macrophages in the plaque,
exclusively in 24-week-old mice (Fig. 3C). The granular stain-
ing further suggested a localization in vesicles in addition to a
patchy localization at the plasma membrane. The absence of
Tcirg1 in the less developed plaques of 16-week-old ApoE/
mice establishes a late manifestation of this osteoclastic func-
tion during plaque formation, as already suggested by our
proteomic results.
Matrisome Remodeling During Atherosclerotic Plaque For-
mation—Structural changes in ECM have been implicated in
the pathogenesis of atherosclerosis and other cardiovascular
diseases (22). Accordingly, we identified matrisomal proteins
to be enriched among significantly regulated proteins during
atherogenesis (p  1016). To investigate the remodeling of
the matrisome in more detail, we first determined matrisome
associated proteins in our data set on the basis of their QDSP
expression profiles (Fig. 4A, Methods). To this end, we filtered
all quantified proteins for at least 2-fold higher expression in
the insoluble fraction (FR4) compared with the average ex-
pression in FR2 and FR3. We also required at least 2-fold
higher MS-signals compared with the average of FR1–3 in at
least one biological condition, which resulted in a set of 532
proteins of a total of 3401 proteins initially identified in FR4
(supplemental Fig. S3, supplemental Table S5). As expected,
there was high enrichment in ECM annotated proteins (p 
1042) (supplemental Table S6), with 25% of proteins being
previously designated as core matrisome or matrisome asso-
ciated proteins (25, 26) (Fig. 4A). Collagens are the main
structural proteins of the ECM and in terms of absolute abun-
dance, Collagen types VI alpha 1–3 (Col6a1–3) were the most
highly expressed ones in aorta, exceeding Collagen types I
alpha 1 and 2 (Col1a1,2) 4-fold and Collagen XV type alpha 1
about eight times (Fig. 4B). Protein-lysine 6-oxidase (Lox) and
Lysyl oxidase homolog 1 (Loxl1), with pivotal roles in the
generation of covalently cross-linked collagen structures were
the most abundant ECM associated enzymes and had levels
comparable to these collagens.
To determine proteins within our ECM related group asso-
ciated with matrisome remodeling, we performed ANOVA on
their expression values in the insoluble fraction over the bio-
logical conditions. This resulted in 65 significantly regulated
matrisome associated proteins in cohort 1 (FDR  0.1, mini-
mum fold change 1.5), whose regulation was closely repro-
duced in cohort 2 (r  0.89) (Fig. 4C, 4D, supplemental Table
S7). Among these proteins we observed strong atherogenesis
dependent up-regulation of Collagen types II alpha1 (Col2a1)
and XII alpha 1 (Col12a1). Collagen types X alpha 1 (Col10a1),
and VIII alpha 1 (Col8a1) were exclusively detected in mature
atherosclerotic aortas from ApoE/mice. This makes them a
specific constituent that contributes to the structure of the
plaque matrisome (supplemental Fig. S4).
Proteases actively shape the ECM and , matrix metallopro-
teases (Mmps) target both core ECM and matrisome associ-
ated proteins (23). Mmp3, Mmp12, and Mmp19 were in-
creased during atherogenesis (Fig. 4C; supplemental Fig. S4).
Up-regulation of Mmp19 has not been reported before,
whereas this is already known for Mmp3 and Mmp12 and
likely derives from macrophage secretion (22). ECM-associ-
ated protease inhibitors were also significantly up-regulated
in atherogenesis, including the tissue inhibitor of metallo-
proteinase 3 (Timp3), which was the most highly expressed
one, as well as two subunits of the Inter-Alpha-Trypsin
Inhibitor, Itih1 and Itih2. Although there is evidence for a
protective role of Timp3 in atherosclerosis (64, 65), Itih1 and
Itih2 have not yet been associated with plaque develop-
ment. The fact that Itih1 was expressed in atherosclerotic
aorta in very similar amounts to Timp3, may further support
a functional role (Fig. 4B).
Apart from proteins connected to known features of plaque
matrisomes, our data set contains factors whose involvement
in this process was completely unknown. For instance, three
matrisomal proteins—Peroxidasin (Pxdn), Matrilin 2 (Matn2),
and MAM Domain Containing 2 (Mamdc2), were expressed at
low levels in wild-type and young ApoE/ mice, but were
specifically up-regulated in ApoE/ mice in the course of
atherogenesis (Fig. 5A, 5B). Mamdc2 is an ECM-associated
protein of unknown function containing four MAM domains,
which can serve as adhesion domains in surface receptors
(66). We validated its up-regulation by IHC and found that it
was expressed in endothelium and tunica media in non-
atherosclerotic aortas and in plaques, concordant with the
increase during atherogenesis in the proteomics data
(Fig. 5C).
DISCUSSION
Atherosclerosis is a multifactorial disease with a high inci-
dence and mortality, and often clinically manifests as stroke
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or myocardial infarction (1–5). A classical animal model for
atherosclerosis is the ApoE/ mouse (40, 41). Depletion of
the ApoE protein leads to spontaneous hypercholesterolemia
and atherogenesis manifested in mature atherosclerotic
plaques. Feeding the mice with high fat diet (“Western diet”)
accelerates atheroprogression. Molecular events related to
vessel maturation happen in conjunction with those related
to atherogenesis. To distinguish between them we followed
a control cohort (wild-type mice on a chow diet) and con-
trasted this to an ApoE/ cohort, fed high fat diet from
week eight.
Because of the proteinaceous nature of plaques, it would
be most promising to investigate how proteins change in
atherogenesis, but so far this has only been done for individ-
ual or small sets of candidate proteins. Here, we employed the
latest advances in proteomics technology to explore this
question. Using aortas from single animals, we obtained
quantitative profiles of thousands of proteins across solubility
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fractions. Although atherosclerotic plaques only constitute a
few percent of aorta mass, their proteome was unambigu-
ously captured by comparison to the wild-type mice. Investi-
gation of three time points was crucial, as it provided a pro-
teome base line in wild-type mice as well as early, purely
genotype related changes, which we contrasted to both gen-
otype and diet-related changes at the point of fully developed
atherosclerosis. Overall, the large majority of atherogenic pro-
teome changes was confined to the 24 week time point—16
weeks after high fat feeding. However, many interesting ef-
fects were clearly apparent at 16 weeks already, such as
those related to lipid metabolism. Apart from providing a
resource of proteome changes in this important disease to the
community, our results suggest that many of the established
mouse models of human diseases can now fruitfully be inter-
rogated by MS-based proteomics.
The protein expression changes in individual aortas in re-
sponse to atherogenesis were overwhelmingly upregulations,
whereas only few proteins showed decrease in expression.
This nonsymmetry can be explained by the de novo develop-
ment of the atherosclerotic plaque, which reflects a buildup of
ECM components by VSMCs together with an infiltration of
immune cells. The increase in protein expression is therefore
the sum of high abundant proteins from immune cells together
with the secretion products of all cell types involved in plaque
formation.
The quantitative detergent solubility profiling (QDSP)
method allowed us to directly measure the compartment as-
sociation of the aorta proteome. Although previous studies
focused on soluble driver proteins in atherogenesis, little is
known about changes in the ECM compartment. In addition to
the increase in Col2a1, Col10a1, and Col12a1, which are
osteoblastic and chondrocytic marker proteins and therefore
likely related to plaque calcification (67, 68), we observed an
atherogenesis specific up-regulation of Col8a1, a protein that
has recently been implicated in fibrous cap formation in ath-
erosclerosis (69). Collagens are organized as highly inter-
linked networks containing both inter- and intramolecular
covalent linkages (29). Peroxidase Pxdn was significantly up-
regulated in atherosclerotic aortas both at the total protein
level and in the insoluble fraction, which is interesting because
it forms collagen IV crosslinked networks in the basement
membrane (70, 71). Thus, an increase in Pxdn might contrib-
ute to the arterial stiffening that is observed in atherosclerosis
(72).
We identified family members of matrix metalloproteinases
(Mmps) with both protective and proatherogenic functions to
be up-regulated during atherogenesis. Although Mmp3 has
been reported to reduce atherosclerotic plaque formation and
rupture (73, 74), Mmp12 promotes plaque development and is
a risk locus for large artery atherosclerotic stroke (75). Mmp19
was found to be protective against bleomycin induced lung
injury in mice (76), therefore its up-regulation during athero-
genesis raises the possibility that it has an atheroprotective
effect. In addition, we found the Mmp inhibitor Timp3 to be
enriched in the insoluble fraction, which has been reported to
protect against atherosclerosis (65).
Among the ECM associated and up-regulated proteins that
have not yet been related to atherogenesis are Matn2 and
Mamdc2. Matn2 is a filament-forming protein widely distrib-
uted in ECM of various tissues, with largely uncharacterized
function that has been linked to muscle and nerve regenera-
tion as well as inflammation (77, 78). Mamdc2 is a proteogly-
can with completely unknown function containing five MAM
domains, which mediate interactions and stability and are
commonly found in surface receptors (79). Our expression
profiles in atherosclerosis make both proteins promising tar-
gets for future studies.
Vascular calcification is a crucial hallmark of atherogenic
plaques that is causally related to clinical outcomes (60, 63)
and here we identified upregulated proteins with known roles
in this process. Vascular calcification is an analogous process
to bone mineralization, involving osteoblast-like cells that are
likely derived from vascular smooth muscle cells (VSMCs)
(80). Up-regulated proteins included the bone matrix protein
Tnfrfs11b, as well as the cartilage matrix proteins Prg4 and
Comp, which serve as intermediates of endochondral bone
formation. In addition, Col12a1 and Col10a1, which mark
sites of bone and cartilage mineralization, respectively, were
enriched in the atherosclerotic ECM. Collectively, these re-
sults support an active osteogenesis and chondrogenesis
calcification model in atherosclerotic plaque development
(63).
In bone, mineralization is a balanced process, which is
negatively regulated by osteoclasts. This has led to long-
standing speculation that similar osteoclast-like cells might be
present in atherogenic plaques and counteract vascular cal-
cification, yet clear evidence for the existence of those cells is
missing (63). Here, we unambiguously identified two subunits
of the osteoclast specific V-ATPase - Tcirg1 (v0a3) and
v0d2-as exclusively expressed in atherosclerotic plaques of
24-week-old ApoE/ mice. The v1b2 subunit of the same
complex, which is also highly expressed in osteoclasts, was
likewise increased in atherosclerotic mouse aortas. Notably,
we observed Tcirg1 expression in macrophages, thus adding
to recent evidence for a role of those cells in mineral clearance
within atherosclerotic plaques (81, 82) and suggesting that
macrophages adapt an osteoclast-like gene expression pro-
gram and providing a possible functional mechanism. Oste-
oclastic V-ATPase is directly involved in bone resorption as it
dissolves minerals through continuous expulsion of H and
Cl ions (83). The osteoclastic V-ATPase might therefore
have an important regulatory function against plaque calci-
fication. This finding may have clinical implications, as in-
hibitors of the osteoclastic V-ATPase have been proposed for
the treatment of osteoporosis (83, 84). Because patients with
osteoporosis also often develop atherosclerosis (85), inhibiting
osteoclastic V-ATPase could unintentionally lead to a detrimen-
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tal increase in plaque calcification. Although our results derive
from an established mouse model, it would be of translational
interest to follow them up in the human system. In this case,
healthy aorta controls would not be available, but this could be
addressed by laser capture based techniques to isolate human
plaques specifically.
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